论文部分内容阅读
目的:探讨特异性尘螨过敏原免疫疗法辅助信必可都保(布地奈德福莫特罗粉吸入剂)雾化吸入治疗中重度支气管哮喘临床效果及安全性。方法:2012年5月—2013年1月选取本院中重度支气管哮喘患者130例,采用随机数字表法分为对照组和试验组,每组65例;其中对照组患者采用信必可都保雾化吸入治疗,试验组患者则在此基础上加用特异性尘螨过敏原免疫疗法;比较两组患者临床疗效,治疗前后肺部通气功能指标,哮喘症状评分、哮喘生活质量评分及治疗期间不良反应发生情况等。结果:试验组患者临床疗效显著优于对照组(P<0.05);两组患者治疗后肺部通气功能指标水平、哮喘症状评分及哮喘生活质量评分较治疗前均显著改善,且试验组患者治疗后各项指标水平优于对照组(P<0.05);两组患者治疗期间不良反应总发生率比较差异无统计学意义(P>0.05)。结论:特异性尘螨过敏原免疫疗法辅助信必可都保雾化吸入治疗中重度支气管哮喘可有效缓解症状体征,提高肺部通气功能和生活质量,且未增加不良反应发生风险。
Objective: To investigate the clinical efficacy and safety of specific dust mite allergen immunotherapy adjunct letter Bixudubao (budesonide formoterol powder inhaler) nebulized inhalation in the treatment of moderate-severe bronchial asthma. Methods: From May 2012 to January 2013, 130 patients with moderate-to-severe bronchial asthma in our hospital were selected and randomly divided into control group and trial group with 65 cases in each group. The patients in the control group were treated with Xinbikudubao At the same time, patients in the experimental group were treated with specific dust mite allergen immunotherapy. The clinical efficacy, lung ventilation function, asthma symptom score, asthma quality of life score and treatment duration before and after treatment were compared between the two groups Adverse reactions occurred. Results: The clinical efficacy of the experimental group was significantly better than that of the control group (P <0.05). After the treatment, the levels of pulmonary ventilation, asthma symptom score and asthma quality of life in both groups were significantly improved after treatment, and the treatment group The level of each index was better than that of the control group (P <0.05). There was no significant difference in the total incidence of adverse reactions between the two groups during treatment (P> 0.05). CONCLUSIONS: Specific Dust Mite Allergen Immunotherapy Supplementary Letter Bcl-2 can all ensure that moderate-to-moderate bronchial asthma inhalation can effectively alleviate symptoms and signs, improve pulmonary ventilation and quality of life without increasing the risk of adverse reactions.